Drugs / URC102
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05198778 | Nov 2021 → Jul 2022 | hypouricemia, renal | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04804111 | Jan 2019 → Sep 2020 | gout | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT02557126 | Oct 2015 → Aug 2016 | gout | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT02290210 | Jul → Dec 2014 | gout | JW Pharmaceutical | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02524678 Comparator | Aug → Oct 2015 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01953497 Comparator | May → Dec 2013 | — | JW Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | URC102 | “3 mg of the URC102 group” NCT04804111 ↗ |
| Action | Inhibit | “URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1)” PMID 31056705 ↗ Nov 2019 |
| Route | Oral | “after single and multiple oral administration” PMID 31056705 ↗ Nov 2019 |